Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:CYCNOTCMKTS:PFSCFNASDAQ:VRCANASDAQ:XENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCYCNCyclerion Therapeutics$3.05$3.10$1.75▼$6.75$8.27M1.843,929 shs132 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AVRCAVerrica Pharmaceuticals$6.85+0.9%$5.72$2.86▼$7.76$290.58M1.88158,575 shs86,259 shsXENEXenon Pharmaceuticals$41.09+2.7%$44.61$27.99▼$50.99$3.10B1.15401,870 shs323,512 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+182.26%CYCNCyclerion Therapeutics-15.14%-13.66%-2.62%-13.91%-50.17%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%VRCAVerrica Pharmaceuticals-2.72%-1.88%+35.53%+17.07%+4.30%XENEXenon Pharmaceuticals+0.33%-3.15%-9.07%-11.19%+1.57%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.5837 of 5 stars3.51.00.04.70.62.50.6XENEXenon Pharmaceuticals1.7355 of 5 stars3.52.00.00.02.22.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsideCYCNCyclerion TherapeuticsN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.00Buy$11.2564.23% UpsideXENEXenon Pharmaceuticals3.00Buy$59.4444.67% UpsideCurrent Analyst RatingsLatest VRCA, XENE, AGLE, CYCN, and PFSCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$62.004/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/10/2024XENEXenon PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.003/1/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/1/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/1/2024XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.003/1/2024XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.003/1/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $62.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00CYCNCyclerion Therapeutics$1.62M5.10N/AN/A$4.62 per share0.66PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08VRCAVerrica Pharmaceuticals$5.12M56.75N/AN/A$0.47 per share14.57XENEXenon Pharmaceuticals$9.43M328.68N/AN/A$14.18 per share2.90Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ACYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/AVRCAVerrica Pharmaceuticals-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)XENEXenon Pharmaceuticals-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)Latest VRCA, XENE, AGLE, CYCN, and PFSCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million 2/29/2024Q4 2023XENEXenon Pharmaceuticals-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59CYCNCyclerion TherapeuticsN/A3.853.85PFSCFProMetic Life SciencesN/A0.950.71VRCAVerrica Pharmaceuticals2.224.554.49XENEXenon PharmaceuticalsN/A23.6523.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ACYCNCyclerion Therapeutics75.62%PFSCFProMetic Life Sciences0.10%VRCAVerrica Pharmaceuticals42.45%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%CYCNCyclerion Therapeutics13.10%PFSCFProMetic Life SciencesN/AVRCAVerrica Pharmaceuticals41.50%XENEXenon Pharmaceuticals5.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataPFSCFProMetic Life Sciences48723.31 millionN/ANot OptionableVRCAVerrica Pharmaceuticals10042.42 million24.82 millionOptionableXENEXenon Pharmaceuticals25175.43 million71.34 millionOptionableVRCA, XENE, AGLE, CYCN, and PFSCF HeadlinesSourceHeadlineFederated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 23 at 5:35 AMInvestors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)americanbankingnews.com - April 18 at 3:04 AMXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 16 at 8:30 AMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analystsamericanbankingnews.com - April 16 at 2:34 AMXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - April 14 at 3:36 AMNeedham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)marketbeat.com - April 12 at 8:14 AMXenon Pharmaceuticals Inc (XENE)investing.com - April 10 at 12:10 PMXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferenceglobenewswire.com - April 10 at 8:30 AMXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 4:01 PMSG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 2 at 4:18 AMAssenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 1 at 4:43 AMXenon Pharmaceuticals Incmoney.usnews.com - March 21 at 10:13 AMXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - March 19 at 8:26 AMXENE Apr 2024 47.500 putfinance.yahoo.com - March 16 at 1:48 PMXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 12 at 4:01 PMInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stockinsidertrades.com - March 11 at 6:41 AMInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...finance.yahoo.com - March 9 at 12:06 AMXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 5 at 4:01 PMBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progressmarkets.businessinsider.com - March 5 at 10:33 AMXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 2:52 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:52 AMXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 1 at 2:30 PMXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focuszacks.com - March 1 at 9:36 AMBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neurosciencemarkets.businessinsider.com - March 1 at 9:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come3 Value Stocks Buffett Wishes He Could BuyApril 22, 2024 8:35 AMView 3 Value Stocks Buffett Wishes He Could BuyGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring PricesAll Headlines Company DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Cyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.ProMetic Life SciencesOTCMKTS:PFSCFPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Xenon PharmaceuticalsNASDAQ:XENEXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.